Telomere length on chromosome 17q shortens more than global telomere length in the development of breast cancer

Neoplasia

Volumn 9, Issue 4, 2007, Pages 265-270

  Rashid Kolvear, Fariborz ^a,b   Pintilie, Melania ^b   Done, Susan J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Breast cancer; Chromosome 17; FISH; Telomerase; Telomere

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST EPITHELIUM; CARCINOMA IN SITU; CHROMOSOMAL INSTABILITY; CHROMOSOME 17Q; CHROMOSOME SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE;

EID: 34247230134     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07106     Document Type: Article

References (26)

1. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, and Wu JR (1988). A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 85, 6622-6626.
2. Autexier C, Pruzan R, Funk WD, and Greider CW (1996). Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA. EMBO J 15, 5928-5935.
3. Cong YS and Bacchetti S (2000). Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 275, 35665-35668.
4. Cong YS, Wen J, and Bacchetti S (1999). The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8, 137-142.
5. Glasspool RM, Burns S, Hoare SF, Svensson C, and Keith NW (2005). The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1A, identifying the transcriptional corepressor CtBP as a potential repressor of both genes. Neoplasia 7, 614-622.
6. Horikawa I, Cable PL, Afshari C, and Barrett JC (1999). Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 59, 826-830.
7. Oh S, Song YH, Kim UJ, Yim J, and Kim TK (1999). In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells. Biochem Biophys Res Commun 263, 361-365.
8. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, and Inoue M (1999). Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59, 551-557.
9. Wick M, Zubov D, and Hagen G (1999). Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 232, 97-106.
10. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A, Menkel AR, and Henriksson M (2001). Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci USA 98, 3826-3831.
11. Shay JW and Bacchetti S (1997). A survey of telomerase activity in human cancer. Eur J Cancer 33, 787-791.
12. Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A, Baumgartner KB, Baumgartner RN, Hunt WC, and Griffith JK (2006). Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat 99, 193-202.
13. Meeker AK, Hicks JL, Gabrielson E, Strauss WM, De Marzo AM, and Argani P (2004). Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol 164, 925-935.
14. Odagiri E, Kanada N, Jibiki K, Demura R, Aikawa E, and Demura H (1994). Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. Cancer 73, 2978-2984.
15. Rogalla P, Rohen C, Bonk U, and Bullerdiek J (1996). Telomeric repeat fragment lengths are not correlated to histological grading in 85 breast cancers. Cancer Lett 106, 155-161.
16. Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, Ulm K, Holzmann B, Nekarda H, and Siewert JR (2004). Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 22, 1807-1814.
17. Tabori U, Vukovic B, Zielenska M, Hawkins C, Braude I, Rutka J, Bouffet E, Squire J, and Malkin D (2006). The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. Neoplasia 8, 136-142.
18. Hemann MT, Strong MA, Hao LY, and Greider CW (2001). The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107, 67-77.
19. Martens UM, Zijlmans JM, Poon SS, Dragowska W, Yui J, Chavez EA, Ward RK, and Lansdorp PM (1998). Short telomeres on human chromosome 17p. Nat Genet 18, 76-80.
20. Perner S, Bruderlein S, Hasel C, Waibel I, Holdenried A, Ciloglu N, Chopurian H, Nielsen KV, Plesch A, Hogel J, et al. (2003). Quantifying telomere lengths of human individual chromosome arms by centromere-calibrated fluorescence in situ hybridization and digital imaging. Am J Pathol 163, 1751-1756.
21. Zou Y, Sfeir A, Gryaznov SM, Shay JW, and Wright WE (2004). Does a sentinel or a subset of short telomeres determine replicative senescence? Mol Biol Cell 15, 3709-3718.
22. Fujii H, Szumel R, Marsh C, Zhou W, and Gabrielson E (1996). Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 56, 5260-5265.
23. Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt MS, and Donis-Keller H (1995). Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 55, 3399-3405.
24. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, et al. (1998). neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16, 1340-1349.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
26. van den Engh G, Sachs R, and Trask BJ (1992). Estimating genomic distance from DNA sequence location in cell nuclei by a random walk model. Science 257, 1410-1412.